What does Definium Therapeutics, Inc. do?
Definium Therapeutics, Inc., a clinical biopharmaceutical company, develops novel product candidates to treat brain health disorders. The company's lead product candidates DT120, which is in phase 3 for the treatment of generalized anxiety disorder, major depressive disorder, and other brain health disorders; and…
What is Definium Therapeutics, Inc.'s P/E and P/B ratio?
Definium Therapeutics, Inc. has a P/E ratio of -10.5 and a P/B ratio of 5.27.
What is Definium Therapeutics, Inc.'s debt-to-equity ratio?
Definium Therapeutics, Inc. has a debt-to-equity ratio of 0.04.
How much does Definium Therapeutics, Inc. owe compared with what it owns?
Definium Therapeutics, Inc. owes $0.17 for every $1 it owns (balance sheet Jun 2026), which is low.
What is Definium Therapeutics, Inc.'s Positivity rank?
Definium Therapeutics, Inc. is ranked #5,310 of 6,774 companies globally and #2,865 of 4,000 in United States on PositoAI, with a Positivity Score of 17,798.
Does Definium Therapeutics, Inc. have any regulatory orders, red flags (PosiRed) or yellow flags (PosiYellow)?
No active red flags (PosiRed) or yellow flags (PosiYellow) are currently on record for Definium Therapeutics, Inc..
Where can I read the latest news about Definium Therapeutics, Inc.?
Recent headlines about Definium Therapeutics, Inc. from the last 30 days, with links to the original articles, are on its News page on PositoAI.
Does Definium Therapeutics, Inc. have a PositoAI PosiShot or QR code?
Yes. A dated PosiShot of Definium Therapeutics, Inc.'s current position, a PosiQR code for its live profile and a ready-made dated mention are available on its For this company page on PositoAI.